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BACKGROUND & AIMS: Microsatellite instability (MSI) and
mismatch-repair deficiency (dMMR) in colorectal tumors are
used to select treatment for patients. Deep learning can
detect MSI and dMMR in tumor samples on routine histology
slides faster and less expensively than molecular assays.
However, clinical application of this technology requires high
performance and multisite validation, which have not yet
been performed. METHODS: We collected H&E-stained slides
and findings from molecular analyses for MSI and dMMR from8836 colorectal tumors (of all stages) included in the MSI-
DETECT consortium study, from Germany, the Netherlands,
the United Kingdom, and the United States. Specimens with
dMMR were identified by immunohistochemistry analyses of
tissue microarrays for loss of MLH1, MSH2, MSH6, and/or
PMS2. Specimens with MSI were identified by genetic ana-
lyses. We trained a deep-learning detector to identify samples
with MSI from these slides; performance was assessed by
cross-validation (N ¼ 6406 specimens) and validated in an
external cohort (n ¼ 771 specimens). Prespecified endpoints
were area under the receiver operating characteristic
(AUROC) curve and area under the precision-recall curve
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Microsatellite instability (MSI) and mismatch-repair
deficiency (dMMR) in colorectal tumors are used to
select treatment for patients. Deep learning can detect
MSI and dMMR in tumor samples on routine histology
slides faster and cheaper than molecular assays.
NEW FINDINGS
We developed a deep-learning system that detects
colorectal tumor specimens with MSI using hematoxylin
and eosin-stained slides; it detected tissues with MSI
with an area under the receiver operating characteristic
curve of 0.96 in a large, international validation cohort.
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specimens with dMMR or MSI with a mean AUROC curve of
0.92 (lower bound, 0.91; upper bound, 0.93) and an AUPRC
of 0.63 (range, 0.59–0.65), or 67% specificity and 95%
sensitivity, in the cross-validation development cohort. In the
validation cohort, the classifier identified samples with dMMR
with an AUROC of 0.95 (range, 0.92–0.96) without image
preprocessing and an AUROC of 0.96 (range, 0.93–0.98) after
color normalization. CONCLUSIONS: We developed a deep-
learning system that detects colorectal cancer specimens
with dMMR or MSI using H&E-stained slides; it detected
tissues with dMMR with an AUROC of 0.96 in a large, in-
ternational validation cohort. This system might be used for
high-throughput, low-cost evaluation of colorectal tissue
specimens.LIMITATIONS
This system requires further validation before it can be
used routinely in the clinic.
IMPACT
This system might be used for high-throughput, low-cost
evaluation of colorectal tissue specimens.Keywords: biomarker; cancer immunotherapy; Lynch syn-
drome; mutation.
ismatch repair deficiency (dMMR) is observed inAbbreviations used in this paper: AUPRC, area under the precision-recall
curve; AUROC, area under the receiver operating curve; CRC, colorectal
cancer; DACHS, Darmkrebs: Chancen der Verhütung durch Screening;
dMMR, deficient mismatch repair; IHC, immunohistochemistry; LS, Lynch
syndrome; MSI, microsatellite instability; NLCS, Netherlands Cohort
Study; PCR, polymerase chain reaction; pMMR, proficient mismatch
repair; QUASAR, Quick and Simple and Reliable; TCGA, The Cancer
Genome Atlas Network; YCR-BCIP, Yorkshire Cancer Research Bowel
Cancer Improvement Programme.
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(CRC) and indicates a biologically distinct type of CRC with
broad prognostic, predictive, and therapeutic relevance.1 In
CRC and other cancer types, dMMR causes microsatellite
instability (MSI), a specific DNA damage pattern. MSI and
dMMR are associated with lack of chemotherapy response
in intermediate stage CRC (pT3–4 N0–2), a reduced inci-
dence of locoregional metastases, and hence the opportunity
of cure by local excision in early-stage disease and a reduced
requirement for adjuvant chemotherapy in stage II disease.
In late-stage disease, MSI and dMMR are predictive of
response to immune checkpoint inhibition and constitute
the only clinically approved pancancer biomarker for
checkpoint inhibition in the United States.2 Furthermore,
MSI and dMMR are the genetic mechanism driving carci-
nogenesis in Lynch syndrome (LS), the most common he-
reditary condition leading to CRC.3 Because of this broad
clinical importance, MSI or dMMR testing is recommended
for all patients with CRC by national and international
guidelines such as the British National Institute for Health
and Care Excellence (NICE) guideline4 and the European
Society for Medical Oncology guidelines.5 However, in clin-
ical practice, only a subset of patients with CRC is investi-
gated for presence of MSI or dMMR because of the high
costs associated with universal testing. This lack of testing
potentially leads to overtreatment with adjuvant chemo-
therapy; underdiagnosis of LS; reduced opportunities to
consider local excision instead of extensive surgery, with
related risks; and morbidity and failure to identify candi-
dates for cancer immunotherapy.
Current laboratory assays for MSI and dMMR testing
involve a multiplex polymerase chain reaction (PCR) assay
or a multiplex immunohistochemistry (IHC) panel. Specif-
ically, MSI can be tested by the Bethesda panel PCR,6
whereas a 4-plex IHC can show absence of 1 of 4
mismatch-repair enzymes (MLH1, MSH2, MSH6, and PMS2).7
However, both assays for MSI or dMMR incur cost,8 require
additional sections of tumor tissue in addition to routineH&E histology,9 and yield imperfect results. The sensitivity
and specificity of these tests have been evaluated in
numerous population-based studies, which are summarized
in current clinical guidelines.10 In these reference studies,
test performance of molecular assays is reported with a
sensitivity of 100% and specificity of 61.1%11 or a higher
specificity of 92.5% with a lower sensitivity of 66.7%12 for
MSI testing. Similarly, for IHC-based tests, sensitivity is re-
ported as 85.7% with a 91.9% specificity in a key study,13
whereas other international guidelines estimate that IHC
testing has a sensitivity of 94% and a specificity of 88%.5
This variable performance of clinical criterion standard
tests indicates that there is need for improvement. In
addition, all available tests incur a substantial cost and
require specialized molecular pathology laboratories. This
highlights the need for new robust, low-cost, and ubiqui-
tously applicable diagnostic assays for MSI or dMMR
detection in patients with CRC.
In routine H&E histologic images, MSI and dMMR tumors
are characterized by distinct morphologic patterns such as
tumor-infiltrating lymphocytes, mucinous differentiation,
heterogeneous morphology, and a poor differentiation.14
Although these patterns are well known to pathologists,
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reliable enough for clinical diagnosis and, therefore, is not
feasible in routine clinical practice.15 In contrast, computer-
based image analysis by deep learning has enabled robust
detection of MSI and dMMR status directly from routine
H&E histology: we recently presented16 and later refined17
such a deep learning assay, which was independently vali-
dated by 2 other groups.18,19 However, all of these studies
used a few hundred patients with CRC at most, but clinical
implementation of a deep learning–based diagnostic assay
requires enhanced sensitivity and specificity to those pre-
viously reported and large-scale validation across multiple
populations in different countries.
To address this, we formed the MSIDETECT consortium: a
group of multiple academic medical centers across and
beyond Europe (http://www.msidetect.eu). In this not-for-
profit consortium, we collected tumor samples from more
than 8000 patients with molecular annotation. The pre-
specified intent was to train and externally validate a deep
learning system for MSI and dMMR detection in CRC. The
primary endpoint was diagnostic accuracy measured by area
under the receiver operating curve (AUROC), area under the
precision-recall curve (AUPRC), and, correspondingly, speci-
ficity at multiple sensitivity levels (99%, 98%, and 95%).Materials and Methods
Ethics Statement and Patient Cohorts
We retrospectively collected anonymized H&E-stained tis-
sue slides of patients with colorectal adenocarcinoma from
multiple previous studies and population registers. For each
patient, at least 1 histologic slide was available, andMSI status or
MMR status was known. We included patients from the
following 4 previous studies with the intent of retraining a
previously described deep learning system.16,17 First, we used
the publicly available Cancer Genome Atlas (TCGA) (n ¼ 616
patients) (Supplementary Figure 1), a multicenter study with
patients with stage I–IV disease, mainly from the United States.20
All images and data from the TCGA study are publicly available
at https://portal.gdc.cancer.gov. Second, we used Darmkrebs:
Chancen der Verhütung durch Screening (DACHS) (n ¼ 2292)
(Supplementary Figure 2), a population-based study of patients
with stage I–IV CRC from southwestern Germany.21 Tissue
samples from the DACHS study were provided by the Tissue
Bank of the National Center for Tumor Diseases (Heidelberg,
Germany) in accordance with the regulations of the tissue bank
and the approval of the ethics committee of Heidelberg Uni-
versity.21,22 Third, we used samples from the Quick and Simple
and Reliable trial (QUASAR) (n ¼ 2206) (Supplementary
Figure 3), which originally aimed to determine survival benefit
from adjuvant chemotherapy in patients from the United
Kingdom with mainly stage II tumors.23 Finally, the Netherlands
Cohort Study (NLCS) (n ¼ 2197) (Supplementary Figure 4)24,25
collected tissue samples as part of the Rainbow-Tissue Micro-
array consortium, and like DACHS, this study included patients
with any tumor stage. All studies were cleared by the institu-
tional ethics board of the respective institutions, as described
before (for QUASAR,23 DACHS,22 and NLCS25).
With the intent of external validation of the deep learning
system, we collected H&E slides from the population-basedYorkshire Cancer Research Bowel Cancer Improvement Pro-
gramme (YCR-BCIP)26 cohort, where routine National Health
Service diagnosis of dMMR was undertaken with further BRAF
mutation and/or hMLH1 methylation screening to identify pa-
tients at high risk of having LS. The primary validation cohort
from YCR-BCIP contained n ¼ 771 patients with standard his-
tology after surgical resection (YCR-BCIP-RESECT)
(Supplementary Figure 5). For an additional exploratory anal-
ysis, we also acquired a nonoverlapping set of n ¼ 1531
patients from YCR-BCIP with endoscopic biopsy samples (YCR-
BCIP-BIOPSY) (Supplementary Figure 6). A set of n ¼ 128
polypectomy samples from the YCR-BCIP study (YCR-BCIP-BI-
OPSY) contained only n ¼ 4 MSI or dMMR patients and was not
used for further analyses because AUROC and AUCPR values
are not meaningful for such low prevalence features. For all
patient samples in YCR-BCIP,26 a fully anonymized, single
scanned image of a representative H&E slide for each patient
was used as a service evaluation study with no access to tissue
or patient data aside from mismatch repair status.
Available clinicopathologic characteristics of all cases in each
cohort are summarized in Supplementary Table 1. MSI status in
the TCGA studywas determined genetically as described before.20
MSI status in the DACHS study was determined genetically with a
3-plex panel as described before.27 In the QUASAR, NLCS, and
YCR-BCIP cohorts, mismatch-repair deficiency (dMMR) or profi-
ciency (pMMR) was determined with a standard immunohisto-
chemistry assays on tissue microarrays as described before (2-
plex for MLH1 and MSH2 in NLCS and QUASAR, 4-plex for
MLH1, MSH2, MSH6 and PMS2 for YCR-BCIP).23 This study com-
plieswith the Transparent Reporting of aMultivariable Prediction
Model for Individual Prognosis or Diagnosis (TRIPOD) statement
as shown in Supplementary Table 2.
Image Preprocessing and Deep Learning
All slides were individually, manually reviewed by trained
observers supervised by expert pathologists to ensure that
tumor tissue was present on the slide and the slide had diag-
nostic quality. Observers and supervisors were blinded
regarding MSI status and any other clinical information. Tumor
tissue was manually outlined in each slide. A small number of
cases were excluded because of insufficient quality, technical
issues, absence of tumor tissue on the observed slide, or lack of
molecular information (Supplementary Figures 1–6). Tumor
regions were tessellated into square tiles of 256-mm edge
length and saved at a resolution of 0.5 mm per pixel using
QuPath, version 0.1.2.28 Initially, the method pipeline was kept
as simple as possible, and color normalization was not used to
preprocess the images. In a slight variation of the initial ex-
periments, all image tiles were color normalized with the
Macenko method29 as described previously.30 A modified
shufflenet deep learning system with a 512  512 input layer
was trained on these image tiles in MATLAB R2019a (Math-
Works, Natick, MA) with the hyperparameters listed in
Supplementary Table 3, as described before.17 Tile-level pre-
dictions were averaged on the patient level, with the proportion
of predicted MSI or dMMR tiles (positive threshold) being the
free parameter for the receiver operating characteristic anal-
ysis. All confidence intervals were obtained by 10-fold boot-
strapping. No image tiles or slides from the same patient were
ever part of the training set and test set. All trained deep learning
classifiers were assigned a unique identifier as listed in
October 2020 Deep Learning Detects Microsatellite Instability 1409
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dx.doi.org/10.5281/zenodo.3627523. Source codes are publicly
available at https://github.com/jnkather/DeepHistology.
Experimental Design
All deep learning experiments (training and test runs) were
prespecified and are listed in Supplementary Table 5. All pa-
tients from TCGA, DACHS, QUASAR, and NLCS were combined
and served as the training set (the international cohort). To
assess the magnitude of batch effects, we trained a deep
learning system on each subcohort in this international training
cohort, assessing intercohort and intracohort performance, the
latter being estimated by 3-fold cross-validation (experiment
1). In addition, we performed a 3-fold cross-validation on the
full international cohort without (experiment 2) and with color
normalization (experiment 2N), which was used for a detailed
subgroup analysis according to predefined clinicopathologic
and molecular subgroups. To identify the optimal number of
patients needed for training, we used the international cohort,
randomly set aside n ¼ 906 patients for testing, and trained on
increasing proportions of the remaining n ¼ 5500 patients
(experiment 3). To evaluate the deep learning system in an
independent, external, population-based cohort, we trained on
the international cohort and tested on YCR-BCIP-RESECT
(experiment 4; this was the primary objective of our study).
This experiment was repeated with color-normalized image
tiles (experiment 4N). YCR-BCIP-RESECT was regarded as the
“holy” test set and was not used for any other purpose than to
evaluate the final classifier. Exploratively, we also evaluated the
final classifier on YCR-BCIP-BIOPSY (experiment 5). Further-
more, to investigate the performance “train-on-biopsy, test-on-
biopsy,” we exploratively trained a 3-fold cross-validated
classifier on YCR-BCIP-BIOPSY (experiment 6).TR
A
Results
Deep Learning Consistently Predicts
Microsatellite Instability in Multiple Patient
Cohorts
In the MSIDETECT consortium, a deep learning system
was trained to predict MSI or dMMR status from digitized
routine H&E whole slide images alone, with ground truth
labels according to local standard procedures (PCR testing
for MSI or IHC testing for dMMR). First, we investigated
deep learning classifier performance in patients of the TCGA,Table 1.Estimating Batch Effects by Analyzing Intracohort and
Cohort
Train on TCGA
n ¼ 426
15% MSI
Tra
Test on TCGA (United States) 0.74 (0.66–0.80) 0.7
Test on QUASAR (United Kingdom) 0.67 (0.64–0.68) 0.8
Test on DACHS (Germany) 0.81 (0.79–0.83) 0.6
Test on NLCS (The Netherlands) 0.77 (0.74–0.79) 0.8
NOTE. Main performance measure AUROC, shown as mean
experiment. Intracohort performance was estimated by 3-fold cDACHS, QUASAR, and NLCS cohorts alone. We found that
training the deep learning system on individual cohorts
yielded an intracohort AUROC of 0.74 (0.66–0.80) in the
TCGA cohort (n ¼ 426), 0.89 (0.86–0.91) in the QUASAR
cohort (n ¼ 1770), 0.92 (0.91–0.94) in the DACHS cohort
(n ¼ 2013), and 0.89 (0.88–0.92) in the NLCS cohort (n ¼
2197 patients) (Supplementary Table 6). This high intra-
cohort performance dropped in some intercohort experi-
ments (Table 1 and experiment 1 in Supplementary Table 5).
Together, these data show that deep learning systems attain
high diagnostic accuracy in single-center cohorts but do not
necessarily generalize to other patient cohorts.Increasing Patient Number Compensates for
Batch Effects and Improves Performance
In the intracohort experiments (Table 1), training on
larger cohorts generally yielded higher performance,
corroborating the theoretical assumption that training on
larger data sets yields more robust classifiers. To quantify
this effect, we merged all patients from TCGA, DACHS,
QUASAR, and NLCS into a large international cohort (N ¼
6406 patients) (Figure 1A). From these digitized whole slide
histology images, we created a library of image tiles for
training deep learning classifiers (Figure 1B). Thus, we
increased the patient number as well as the data hetero-
geneity due to different preanalytic pipelines in the
respective medical centers. We set aside a randomly chosen
proportion of n ¼ 906 of these patients and retrained deep
learning classifiers on 500, 1000, 1500, and so on, up to
5500 patients of the international cohort. In this experi-
ment, we found that AUROC (Figure 1C) and AUPRC
(Supplementary Figure 7) on the test set initially increased
as the number of patients in the training set increased.
However, each increase in patient number yielded dimin-
ishing performance returns, and AUROC and AUPRC pla-
teaued at approximately 5000 patients (Figure 1D). The top
performance was achieved by training on 5500 patients and
testing on the fixed test set of n ¼ 906 patients, with an
AUROC of 0.92 (0.90–0.93) (compared to a baseline of 0.5
by a random model) (Figure 1C), an AUPRC of 0.59 (0.4–
0.63) (compared to a baseline of 0.12 in a random model)
(Supplementary Figure 7 and experiment 3 in
Supplementary Table 5), translating to a specificity of 52%
at a sensitivity of 98%. To ensure that this performance wasIntercohort Performance in all Subcohorts in the International
in on QUASAR
n ¼ 1770
14% dMMR
Train on DACHS
n ¼ 2013
14% MSI
Train on NLCS
n ¼ 2197
10% dMMR
6 (0.70–0.79) 0.77 (0.73–0.79) 0.72 (0.71–0.78)
9 (0.86–0.91) 0.71 (0.68–0.75) 0.76 (0.73–0.78)
8 (0.65–0.72) 0.92 (0.91–0.94) 0.80 (0.78–0.82)
0 (0.78–0.81) 0.82 (0.79–0.83) 0.90 (0.89–0.91)
with lower and upper bounds in a 10-fold bootstrapped
ross-validation.
Figure 1. Deep learning workflow and learning curves. (A) Histologic routine images were collected from 4 large patient co-
horts. All slides were manually quality checked to ensure the presence of tumor tissue (outlined in black). (B) Tumor regions
were automatically tessellated, and a library of millions of nonnormalized (native) image tiles was created. (C) The deep learning
system was trained on increasing numbers of patients and evaluated on a random subset (n ¼ 906 patients). Performance
initially increased by adding more patients to the training set but reached a plateau at approximately 5000 patients. (D) Cross-
validated experiment on the full international cohort (comprising TCGA, DACHS, QUASAR, and NLCS). Receiver operating
characteristic (ROC) with true positive rate shown against false positive rate AUROC is shown on top. (E) ROC curve (left) and
precision-recall curve (right) of the same classifier applied to a large external data set. High test performance was maintained in
this data set, and thus, the classifier generalized well beyond the training cohorts. The black line indicates average perfor-
mance, the shaded area indicates bootstrapped confidence interval, and the red line indicates random model (no skill). FPR,
false positive rate; TPR, true positive rate;
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performed a patient-level 3-fold cross-validation on the full
international cohort (N ¼ 6406), reaching a similar mean
AUROC of 0.92 (0.91–0.93( (Figure 1D and experiment 2 in
Supplementary Table 5). Together, these data show that
approximately 5000 patients are necessary and sufficient to
train a high-quality deep learning detector of MSI and dMMR.Clinical-Grade Performance in an External Test
Cohort
Deep learning systems are prone to overfit to the data
set they were trained on and, thus, must be validated in
external test sets. Correspondingly, the prespecified pri-
mary endpoint of this study was the test performance in acompletely independent set of patients. This set of patients
was intended to be population-based, that is, to mirror the
clinicopathologic characteristics of a real-world screening
population. It was used for no other purpose than to
validate the final classifier, which was previously trained
on the international cohort. The test set comprised routine
H&E slides from the population-based YCR-BCIP study
(YCR-BCIP-RESECT, n ¼ 771 patients, 1 slide per patient).
In this population, we found a high classification perfor-
mance with a mean AUROC of 0.95 and (0.92–0.96) lower
and upper bootstrapped confidence bounds, respectively
(Figure 1E and Supplementary Table 6, experiment 4).
Because the target feature MSI and dMMR are unbalanced
in real-world populations such as YCR-BCIP-RESECT, we
also assessed the precision-recall characteristics of this test,
Figure 2. Cross-validated subgroup analysis for the detection of MSI and dMMR in the international cohort (N ¼ 6406 pa-
tients). AUC, area under the receiver operating curve as shown in the image; FPR, false positive rate; MUT, mutated; TPR, true
positive rate; WT, wild type.
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to the baseline AUPRC of 0.14 of the null model in this
cohort. These data show that a deep learning system trained
on a large and heterogeneous international training cohort
generalizes well beyond the training set and thus consti-
tutes a tool of potential clinical applicability.Prediction Performance Is Robust in
Clinicopathologic and Molecular Subgroups
CRC comprises a number of anatomically and biologi-
cally distinct molecular subgroups, including right- and
left-sided colon cancer, rectal cancer, and BRAF-driven and
RAS-driven tumors, among others. This is especially relevant
because these features are partially dependent on each
other; for example, BRAF mutations and right-sidedness are
associated with MSI status.31,32 To assess if image-based
MSI prediction is robust across these heterogeneous sub-
groups, we used the cross-validated deep learning system
(experiment 2 in Supplementary Table 5) and comparedAUROC and AUPRC across subgroups (Figure 2 and
Supplementary Figure 8). We found some variation in
classifier performance regarding anatomic location: the
AUROC was 0.89 for right-sided cancer (n ¼ 2371 patients),
0.88 for left-sided cancer (n ¼ 3846), 0.91 for colon cancer
overall (n ¼ 4408), and 0.83 for rectal cancer (n ¼ 1938).
Little variation was observed in classifier performance ac-
cording to molecular features: AUROC was 0.86 in BRAF
mutants (n ¼ 298) and 0.91 in BRAF wild type (n ¼ 3226);
also, AUROC was 0.90 in KRAS mutants (n ¼ 1263) and 0.93
in KRAS wild-type tumors (n ¼ 2248). Finally, we analyzed
the robustness of MSI predictions for different Union for
International Cancer Control stages, showing stable perfor-
mance with an AUROC of 0.93 in stage I (n ¼ 871), 0.92 in
stage II (n ¼ 3261), and 0.91 in stage III (n ¼ 1554) tumors
and a minor reduction of performance in patients with stage
IV tumors ( n ¼ 636), reaching an AUROC of 0.83. In addi-
tion, histologic grading (Supplementary Figure 9) did not
influence classification performance. Next, we asked if this
robust performance across subgroups was maintained in
Figure 3. Effect of color normalization on classifier performance. (A) A representative set of tiles from the MSIDETECT study.
(B) The same tiles after color normalization. (C) Classifier performance on an external test set (YCR-BCIP-RESECT, n ¼ 771
patients) improves after color normalizing the training and test sets. Experiment 4N is with color normalization; experiment 4 is
without color normalization. FPR, false positive rate; TPR, true positive rate.
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tients). Again, in this cohort, we did not find any relevant
loss in performance with regard to the following subgroups:
tumor stage, organ, anatomical location, and sex
(Supplementary Figures 10 and 11). In summary, this
analysis shows and quantifies variations in performance
according to CRC subgroups but demonstrates that overall,
MSI and dMMR detection performance is robust.Application of the Deep Learning System to
Biopsy Samples
As additional exploratory endpoints, we tested if a deep
learning system trained on histologic images from surgical
resections can predict MSI and dMMR status of images from
endoscopic biopsy tissue. Biopsy samples include technical
artifacts (fragmented tissue and small tissue area)
(Supplementary Figure 12A) as well as biological artifacts
(sampled from the luminal portions of the tumor only). We
acquired endoscopic biopsy samples from n¼ 1557 patients
in the YCR-BCIP-BIOPSY study and tested the resection-
trained classifier (experiment 5 in Supplementary
Table 6). We found that AUROC was reduced to 0.78
(0.75–0.81) (Supplementary Figure 12B) in this experiment.
In a 3-fold cross-validated experiment on all n ¼ 1531 pa-
tients in the YCR-BCIP-BIOPSY cohort, MSI and dMMRdetection performance was restored to an AUROC of 0.89
(0.88–0.91) (experiment 6 in Supplementary Table 5).
These data suggest that MSI and dMMR testing on biopsy
samples requires a classifier trained on biopsy samples.Color Normalization Improves External Test
Performance
Because previous studies have pointed to a benefit of
color normalizing histology images before quantitative
analysis,29 the main experiments in this study were
repeated on color-normalized image tiles. Native (non-
normalized) image tiles (Figure 3A) were subjectively more
diverse in terms of staining hue and intensity than
normalized tiles (Figure 3B). Repeating MSI and dMMR
prediction by 3-fold cross-validation on the full interna-
tional cohort with color-normalized tiles (experiment 2N in
Supplementary Table 5), we found that color normalization
modestly improves specificity at predefined sensitivity
levels: specificity was 57% at 99% sensitivity in experiment
2N, as opposed to a specificity of 38% at 99% sensitivity in
the corresponding nonnormalized experiment (2). However,
this increase in specificity did not result in a higher AUROC
overall (Supplementary Table 5). To test if color normali-
zation improves the external test performance of MSI and
dMMR predictors, we repeated experiment 4 (training on full
Figure 4. Prediction map in the external test cohort YCR-BCIP-RESECT. (A–C) Representative images from the YCR-BCIP-
RESECT test cohort labeled with immunohistochemically defined mismatch repair (MMR) status. (D–F) Corresponding deep
learning prediction maps. The edge length of each prediction tile is 256 mm. (G–I) Higher magnification of the regions high-
lighted in A-E. True MSI or dMMR patients were strongly and homogeneously predicted to be MSI or dMMR (such as the
patient shown in A). True MSS or pMMR patients were overall predicted to be MSS or pMMR (such as the patients in B and C),
but a pronounced heterogeneity was observed in necrotic areas, poorly differentiated areas, and immune-infiltrated tumor
areas at the invasive edge.
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after color normalization (experiment 4N). In this case,
AUROC did improve (no normalization in 4: AUROC, 0.95
[0.92–0.96]; color normalization in 4N: AUROC, 0.96 [0.93–
0.98]). This slight increase in AUROC translated into a higher
specificity at predefined sensitivity levels, reaching 58%
specificity at 99% sensitivity (Supplementary Table 5). These
data show that color normalization can further improve
classifier performance and improve generalizability of deep
learning–based inference of MSI and dMMR status.
Discussion
A Clinical-Grade Deep Learning–Based
Molecular Biomarker in Cancer
Analyzing more than 8000 patients with CRC in an in-
ternational consortium, we show that deep learning can
reliably detect MSI and dMMR tumors based on routine H&E
histology alone. In an external validation cohort, the deep
learning MSI and dMMR detector performed with similar
characteristics to criterion standard tests,12 reachingclinical-grade performance. As shown in previous studies,16
it can be assumed that this deep learning–based method can
be less expensive and faster than routine laboratory assays
and therefore has the potential to improve clinical diag-
nostic workflows. Our data show that classifier performance
in surgical specimens remains robust even when the clas-
sifier is applied to external cohorts, but performance is
lower in biopsy samples where tissue areas are much
smaller than those of surgically resected specimens. This
highlights the need to perform thorough large-scale evalu-
ation of deep learning–based biomarkers in each intended
use case. Deep learning histology biomarkers such as the
MSI and dMMR detection system can be made under-
standable by visualization of prediction maps (Figure 4A–I)
or by visualizing highly scoring image tiles (Supplementary
Figure 13A and B). Together, these approaches show that
the deep learning system yielded plausible predictions. For
example, high MSI or dMMR scores were assigned to poorly
differentiated tumor tissue (Supplementary Figure 13A),
whereas high microsatellite stable or pMMR scores were
assigned to well-differentiated areas. Interestingly, the
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degrees of heterogeneity: in all analyzed true positive MSI
and dMMR cases in the YCR-BCIP-RESECT validation cohort,
we found a homogeneously strong prediction of MSI and
dMMR, as shown in Figure 4A and D. In contrast, predictions
in true MSS and pMMR cases were more heterogeneous.
Necrotic, poorly differentiated, or immune-infiltrated areas
tended to be falsely predicted to be MSI or dMMR (Figure 4C
and F). However, because patient-level predictions reflected
overall scores in the full tumor area, most true MSS and
pMMR patients were correctly predicted after pooling tile-
level predictions, despite some degree of tile-level
heterogeneity.Clinical Application: Prescreening or Definitive
Testing
In this study, diagnostic performance was stable across
multiple clinically relevant subgroups, except for lower-
than-average performance in patients with rectal cancer,
possibly due to neoadjuvant pretreatment of some of these
patients. In summary, this study defines a thoroughly vali-
dated deep learning system for genotyping CRC based on
histology images alone, which could be used in clinical
settings after regulatory approval. By varying the operating
threshold, sensitivity and specificity of this test can be
changed according to the clinical workflow this test is
embedded in: high-sensitivity deep learning assays could be
used to prescreen patients and could trigger additional ge-
netic testing in the case of positive predictions. Even with
imperfect specificity, such classifiers could speed up the
diagnostic workflow and provide immediate cost savings,
especially in the context of universal MSI and dMMR testing,
as recommended by clinical guidelines. Recent discussions
and calculations on the cost effectiveness of systematic MSI
or dMMR testing in patients with CRC33 should incorporate
deep-learning–based assays among the other strategies in
the future.
Alternatively, deep learning biomarkers such as the
method presented in this study could be used for definitive
testing in the clinic, especially in health care settings where
limited resources are currently prohibitive for universal
molecular biology tests. Further studies are needed to
determine the optimal operating thresholds for specific
patient populations and clinical settings. In addition, clinical
deployment will require prospective validation and regula-
tory approval. Ultimately, this method should rapidly iden-
tify MSS and pMMR cases with high certainty and identify
high risk MSI, dMMR, and possible LS cases for confirmation
by other tests. This could substantially reduce molecular
testing load in clinical workflows and enable direct, uni-
versal, low-cost MSI and dMMR testing from ubiquitously
available routine material.
Technical improvements could conceivably further
improve performance and open up new clinical applica-
tions. In this study, we explored color normalization as a
way of reducing heterogeneity in staining intensity and hue
between patient cohorts. This intervention (experiment 4N
in Supplementary Table 5) modestly improvedperformance, increasing specificity from 51% to 58% at
99% sensitivity in an external validation cohort. The deep
learning system and the source codes used in this study
have been publicly released, enabling other researchers to
independently validate and, potentially, further improve its
performance.Limitations
A limitation to our experimental workflow is that the
ground truth labels used to train the deep learning system
are imperfect. In the MSIDETECT group, clinical routine
assays were used to assess MSI or dMMR status, and these
assays have a nonzero error rate. Correspondingly, classifier
performance could suffer from noisy labels in the training
data. On the other hand, test cases flagged as false positive
could be true MSI or dMMR cases that were missed by the
clinical criterion standard test. Ultimately, it is conceivable
that deep learning assays can outperform classical genetic
or molecular tests in terms of predictive and prognostic
performance, but testing this hypothesis would require
large cohorts with clinical endpoint data and/or deep ge-
netic characterization. In particular, the deep learning clas-
sifier could potentially detect rare genetic aberrations with
MSI-like morphology, but again, lack of large training co-
horts for these rare features currently precludes deeper
investigation of this aspect. Another potential limitation of
this study is the performance in patient groups of potential
clinical interest that were not analyzed in the subgroup
analysis, such as hereditary vs sporadic MSI and dMMR
cases or different ethnic backgrounds. This is due to the lack
of available clinical data in the utilized patient cohorts, and
future studies are needed to investigate the stability of deep
learning–based prediction in these and further
subpopulations.
Interestingly, when we analyzed the per-patient pre-
dictions of MSI status in the external test set (YCR-BCIP-
RESECT), we found an outlier among the false negative
predictions: patient 441999 had a very low “predicted MSI
probability” of less than 15%, whereas all other “true MSI”
patients had MSI probability scores of more than 40%. We
went back to the original histology slide of patient 441999
and noticed that a technical artifact had resulted in a blur-
red image, which was visible at only high magnification and
had thus gone undetected in the manual quality check. This
shows that an improved quality control at multiple magni-
fication levels could increase the sensitivity of the deep
learning assay, maintaining a high specificity.
Finally, a possible practical challenge in further valida-
tion and future integration of the deep learning methods in
a clinical workflow is the current lack of regular installation
of slide scanners in hospitals. However, in the United
Kingdom and other countries, large academic consortia are
currently implementing nationwide digital pathology
workflows. This trend can be expected to further accelerate
and will be supported by clinically useful applications of
deep learning technology, especially after regulatory
approval of such tools.34 Still, initially it is probably more
realistic to establish central testing facilities that are
October 2020 Deep Learning Detects Microsatellite Instability 1415equipped with slide scanners and the further hardware
needed for deep learning applications. In this setting,
smaller hospitals and medical centers would not be con-
fronted with high fixed costs but only with expenses and
work that come with the distribution of H&E glass slides to
central testing facilities.C
AN
D
TI
ON
AL
ATContext: Multicenter Validation of Deep Learning
Biomarkers
Recent years have seen a surge of deep learning
methods in digital pathology, but previous large-scale
studies are limited to simple image analysis tasks such as
tumor detection35 and do not extend to scenarios of mo-
lecular biomarker detection. Smaller proof-of-concept
studies have shown that deep learning can detect a range
of molecular biomarkers directly from routine histology,
including multiple clinically relevant oncogenes.17–19
However, these classifiers were not validated in large
multicenter cohorts and cannot be readily generalized
beyond the training set. To our knowledge, the present
study is the first international collaborative effort to vali-
date such a deep learning–based molecular biomarker. It
identifies the need for very large series; training on a va-
riety of sample types, such as resection and biopsy; and
different populations. The high performance in this
particular use case yields a tool of immediate clinical
applicability and provides a blueprint for the emerging
class of deep learning–based molecular tests in oncology,
with the potential to broadly improve workflows in pre-
cision oncology worldwide.BA
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TR
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SL
A
Supplementary Material
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Supplementary Figure 1. Sample flowchart for the TCGA
cohort.
Supplementary Figure 2. Sample flowchart for the DACHS
cohort.
Supplementary Figure 3. Sample flowchart for the QUASAR
cohort.
Supplementary Figure 4. Sample flowchart for the NLCS
cohort.
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Supplementary Figure 5. Sample flowchart for the external test cohort YCR-BCIP. The primary intention of our study was to
validate the MSI detection classifier in the surgical resection samples. As an explorative analysis, we validated the classifier in
endoscopic biopsy samples. Polypectomy samples were not assessed because of a low relative proportion and absolute
number of positive cases.
Supplementary Figure 6. AUPRC for the learning curve
experiment. Includes experiment 3, related to Figure 1C.
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Supplementary Figure 7.Cross-validated subgroup analysis in TCGA, DACHS, and QUASAR: precision-recall curves. Related to
Figure 2. The red line indicates baseline (random) model with no skill. MUT, mutated; PPV, positive predictive value; WT, wild type.
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Supplementary Figure 8. Subgroup analysis for MSI and dMMR detection according to histologic grading. (A–D) Receiver
operating characteristic analysis for subgroups of patients stratified by histologic grading G1–G4. Related to experiment 2.
Grading information was available only for patients in the DACHS cohort. FPR, false positive rate; TPR, true positive rate.
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Supplementary Figure 9. Subgroup analysis of MSI detection performance in the test set (YCR-BCIP-RESECT), Receiver
operating characteristic curves.
Supplementary Figure 10. Subgroup analysis of MSI detection performance in the test set (YCR-BCIP-RESECT): precision-
recall curves.
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Supplementary Figure 11. Classifier performance in biopsy samples (YCR-BCIP biopsy). (A) Representative whole slide
image; brightness and contrast have been linearly increased for better visibility (þ20%). This examples shows that endoscopic
biopsy tissue is usually fragmented. (B) Receiver operating characteristic curve related to experiment 5 in Supplementary
Table 5. (C) Receiver operating characteristic curve related to experiment 6 in Supplementary Table 5.
Supplementary Figure 12. Highly scoring tiles by MSI and MMR status. (A) The 5 highest scoring image tiles in the 5 highest
scoring MSI or dMMR patients in the YCR-BCIP-RESECT cohort from experiment 4 in Supplementary Table 5. (B) Corre-
spondingly, the highest scoring non-MSI tiles in the highest scoring non-MSI patients.
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Supplementary Table 1.Clinicopathologic Features of Each Cohort
DACHS QUASAR TCGA NLCS
YCR-BCIP-
RESECT
YCR-BCIP-
BIOPSY
YCR-BCIP-
POLYP
Number of patients 2013 1770 426 2197 771 1531 128
Region Germany United Kingdom United States The Netherlands United Kingdom United Kingdom United Kingdom
WSI format SVS SVS SVS MRXS SVS SVS SVS
MSI or dMMR PCR 3-plex IHC
2-plex
Genetica IHC
2-plex
IHC
4-plex
IHC
4-plex
IHC
4-plex
Mean age at diagnosis, y 68.8 62.2 65.6 73.8 70.5 71.9 67.8
MSI positive, n (%) 207 (10.3) 246 (13.9) 63 (14.8) 228 (10.4) 111 (14.39) 210 (13.72) 4 (3.13)
Stage I, n (%) 369 (18.3) 0 (0.0) 67 (15.7) 435 (19.8) 151 (19.6) Unknown Unknown
Stage II, n (%) 674 (33.5) 1608 (90.8) 154 (36.2) 825 (37.6) 277 (35.9) Unknown Unknown
Stage III, n (%) 690 (34.3) 156 (8.8) 133 (31.2) 575 (26.2) 313 (40.6) Unknown Unknown
Stage IV, n (%) 280 (13.9) 0 (0.0) 59 (13.8) 297 (13.5) 0 (0.0) Unknown Unknown
Male, n (%) 1161 (57.7) 1073 (60.6) 211 (49.5) 1223 (55.7) 415 (53.8) 912 (59.6) 89 (69.5)
Female, n (%) 852 (42.3) 692 (39.1) 213 (50.0) 974 (44.3) 356 (46.2) 615 (40.2) 38 (29.7)
Colon cancer, n (%) 1260 (62.6) 1274 (72.0) 321 (75.4) 1553 (70.7) 579 (75.1) 858 (56.0) 69 (53.9)
Rectal cancer, n (%) 753 (37.4) 436 (24.6) 105 (24.6) 644 (29.3) 187 (24.3) 658 (43.0) 59 (46.1)
BRAF mutant, n (%) 138 (6.9) 104 (5.9) 56 (13.1) Unknown Unknown Unknown Unknown
BRAF wild type, n (%) 1711 (85.0) 1145 (64.7) 370 (86.9) Unknown Unknown Unknown Unknown
KRAS mutant, n (%) 606 (30.1) 465 (26.3) 192 (45.1) Unknown Unknown Unknown Unknown
KRAS wild type, n (%) 1264 (62.8) 750 (42.4) 234 (54.9) Unknown Unknown Unknown Unknown
MRXS, Mirax Digital Slide Format; SVS, Aperio SVS file format; WSI, whole slide image.
aLiu Y, Sethi NS, Hinoue T, et al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell
2018;33:721–735.
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Supplementary Table 2.TRIPOD checklist
Section/Topic Item Checklist Item
Title and abstract
Title 1 D;V Identify the study as developing and/or validating a multivariable
prediction model, the target population, and the outcome to be
predicted.
Abstract 2 D;V Provide a summary of objectives, study design, setting, participants,
sample size, predictors, outcome, statistical analysis, results,
and conclusions.
Introduction
Background and
objectives
3a D;V Explain the medical context (including whether diagnostic or
prognostic) and rationale for developing or validating the
multivariable prediction model, including references to existing
models.
3b D;V Specify the objectives, including whether the study describes the
development or validation of the model or both.
Methods
Source of data 4a D;V Describe the study design or source of data (e.g., randomized trial,
cohort, or registry data), separately for the development and
validation data sets, if applicable.
4b D;V Specify the key study dates, including start of accrual; end of
accrual; and, if applicable, end of follow-up.
Participants 5a D;V Specify key elements of the study setting (e.g., primary care,
secondary care, general population) including number and
location of centres.
5b D;V Describe eligibility criteria for participants.
5c D;V Give details of treatments received, if relevant.
Outcome 6a D;V Clearly define the outcome that is predicted by the prediction model,
including how and when assessed.
6b D;V Report any actions to blind assessment of the outcome to be
predicted.
Predictors 7a D;V Clearly define all predictors used in developing or validating the
multivariable prediction model, including how and when they
were measured.
7b D;V Report any actions to blind assessment of predictors for the
outcome and other predictors.
Sample size 8 D;V Explain how the study size was arrived at.
Missing data 9 D;V Describe how missing data were handled (e.g., complete-case
analysis, single imputation, multiple imputation) with details of
any imputation method.
Statistical analysis methods 10a D Describe how predictors were handled in the analyses.
10b D Specify type of model, all model-building procedures (including any
predictor selection), and method for internal validation.
10c V For validation, describe how the predictions were calculated.
10d D;V Specify all measures used to assess model performance and, if
relevant, to compare multiple models.
10e V Describe any model updating (e.g., recalibration) arising from the
validation, if done.
Risk groups 11 D;V Provide details on how risk groups were created, if done.
Development vs. validation 12 V For validation, identify any differences from the development data in
setting, eligibility criteria, outcome, and predictors.
Results
Participants 13a D;V Describe the flow of participants through the study, including the
number of participants with and without the outcome and, if
applicable, a summary of the follow-up time. A diagram may be
helpful.
13b D;V Describe the characteristics of the participants (basic demographics,
clinical features, available predictors), including the number of
participants with missing data for predictors and outcome.
13c V For validation, show a comparison with the development data of the
distribution of important variables (demographics, predictors and
outcome).
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Section/Topic Item Checklist Item
Model development 14a D Specify the number of participants and outcome events in each
analysis.
14b D If done, report the unadjusted association between each candidate
predictor and outcome.
Model specification 15a D Present the full prediction model to allow predictions for individuals
(i.e., all regression coefficients, and model intercept or baseline
survival at a given time point).
15b D Explain how to the use the prediction model.
Model performance 16 D;V Report performance measures (with CIs) for the prediction model.
Model-updating 17 V If done, report the results from any model updating (i.e., model
specification, model performance).
Discussion
Limitations 18 D;V Discuss any limitations of the study (such as nonrepresentative
sample, few events per predictor, missing data).
Interpretation 19a V For validation, discuss the results with reference to performance in
the development data, and any other validation data.
19b D;V Give an overall interpretation of the results, considering objectives,
limitations, results from similar studies, and other relevant
evidence.
Implications 20 D;V Discuss the potential clinical use of the model and implications for
future research.
Other information
Supplementary information 21 D;V Provide information about the availability of supplementary
resources, such as study protocol, Web calculator, and data
sets.
Funding 22 D;V Give the source of funding and the role of the funders for the present
study.
Supplementary Table 3.Description and Values of All Hyperparameters and Properties of the Deep Learning Workflow
Hyperparameter Description Value
Network architecture Deep neural network layout shufflenet
Tile size Size of image tiles on the whole slide image 256 mm
Tile magnification Image magnification of the tiles 0.5 mm/pixel
Effective tile size Size of image tile files for training 512 px
Tiles per slide Limit the number of randomly picked tiles 1000 (single cohort)
1000 (learning curve)
500 (combined)
Maximum epochs Maximum number each image tile is shown to the network during training 4
Trainable layers Number of network layers with nonzero learning rate, counted from the end 30
Validation fraction Use some training tiles as a validation set to mitigate overfitting 0% (single cohort)
5% (learning curve)
5% (combined)
Graphics processing unit Graphics processing unit hardware NVidia RTX6000
Initial learn rate Network learning rate during training 5  10–5
L2 regularization L2 regularization to mitigate overfitting 0.0001
Mini batch size Number of image tiles processes in parallel 512
Solver Optimizer to update weights and biases adam
NOTE. Single-cohort models were trained on 1 study population only (eg, QUASAR), whereas combined cohort experiments
were trained on patients across cohorts. Parameters for the learning curve experiment refer to Figure 1D.
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Supplementary Table 4.Unique Identifiers of Downloadable Models
Unique model identifier Trained on Additional information
HWSLMTNSRQSY TCGA (n ¼ 426, 15% MSI) Used to quantify batch effect
1000 tiles per slide
QWAFEDQLFICH QUASAR (n ¼ 1770, 14% dMMR) Used to quantify batch effect
1000 tiles per slide
YGREQLWMWSLR DACHS (n ¼ 2013, 14% MSI) Used to quantify batch effect
1000 tiles per slide
VKTALAYFITSN NLCS (n ¼ 2197, 10% dMMR) Used to quantify batch effect
1000 tiles per slide
HLVDDREQHWQK International cohort, nonnormalized (TCGA þ
QUASAR þ DACHS þ NLCS)
This is the final model deployed on the external test cohorts
500 tiles per slide.
AWAMMGTGLNAF International cohort, color normalized (TCGA þ
QUASAR þ DACHS þ NLCS)
This is the final model deployed on the external test cohorts
500 tiles per slide.
NOTE. All deep learning models trained in this study are freely available for academic reuse.
Supplementary Table 5.Performance Statistics for All Experiments Described in This Article
ID Experiment description Result statistics
#1 Estimate intracohort and intercohort performance for all subcohorts in the
international cohort (Total N ¼ 6406, 12% MSI or dMMR)
See Table 1
#2 3-fold cross-validation on full international cohort (Total N ¼ 6406, 12% MSI or
dMMR)
AUROC: 0.92 (0.91–0.93)
AUPRC: 0.63 (0.59–0.65)
Sensitivity: 99%, specificity: 38%
Sensitivity: 98%, specificity: 48%
Sensitivity: 95%, specificity: 67%
#2N 3-fold cross-validation on full international cohort (with color normalization) AUROC: 0.92 (0.91–0.93)
AUPRC: 0.63 (0.61–0.66)
Sensitivity: 99%, specificity: 57%
Sensitivity: 98%, specificity: 78%
Sensitivity: 95%, specificity: 83%
#3 Train on n ¼ 5500 international patients
Test on n ¼ 906 international patients (Test set 12% MSI or dMMR, last part of
learning curve)
AUROC: 0.92 (0.90–0.93)
AUPRC: 0.59 (0.49–0.63)
Sensitivity: 99%, specificity: 49%
Sensitivity: 98%, specificity: 52%
Sensitivity: 95%, specificity: 68%
#4 Train on the full international cohort (N ¼ 6406, 12% MSI or dMMR, model ID:
HLVDDREQHWQK)
External test on YCR-BCIP-RESECT (test set n ¼ 771, 14% dMMR)
AUROC: 0.95 (0.92–0.96)
AUPRC: 0.79 (0.74–0.86)
Sensitivity: 99%, specificity: 51%
Sensitivity: 98%, specificity: 66%
Sensitivity: 95%, specificity: 74%
#4N Train on the full international cohort (model ID: AWAMMGTGLNAF)
External test on YCR-BCIP-RESECT (with color normalization)
AUROC: 0.96 (0.93–0.98)
AUPRC: 0.85 (0.829–0.90)
Sensitivity: 99%, specificity: 58%
Sensitivity: 98%, specificity: 79%
Sensitivity: 95%, specificity: 86%
#5 Train on the full international cohort (N ¼ 6406, 12% MSI or dMMR, model ID:
HLVDDREQHWQK)
External test on YCR-BCIP-BIOPSY (test set n ¼ 1531, 14% dMMR)
AUROC: 0.78 (0.75–0.81)
AUPRC: 0.37 (0.32–0.43)
Sensitivity: 99%, specificity: 19%
Sensitivity: 98%, specificity: 20%
Sensitivity: 95%, specificity: 25%
#6 3-fold cross-validation on YCR-BCIP-BIOPSY (Concatenate test partitions, total
n ¼ 1531, 14% dMMR)
AUROC: 0.89 (0.88–0.91])
AUPRC: 0.58 (0.56–0.61)
Sensitivity: 99%, specificity: 35%
Sensitivity: 98%, specificity: 38%
Sensitivity: 95%, specificity: 56%
NOTE. Detailed performance statistics, corresponding to Figure 2. No patient in a training set was ever part of a test set in the
same experiment. Experiment 4 was the prespecified primary endpoint of this study.
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Supplementary Table 6.The Rainbow-TMA Consortium Associated With the NLCS Study
Rainbow-TMA
project group
P.A. van den Brandt, A. zur Hausen, H. Grabsch, M. van Engeland, L.J. Schouten, J. Beckervordersandforth
(Maastricht University Medical Center, Maastricht, Netherlands); P.H.M. Peeters, P.J. van Diest, H.B. Bueno de
Mesquita (University Medical Center Utrecht, Utrecht, Netherlands); J. van Krieken, I. Nagtegaal, B. Siebers, B.
Kiemeney (Radboud University Medical Center, Nijmegen, Netherlands); F.J. van Kemenade, C. Steegers,
D. Boomsma, G.A. Meijer (VU University Medical Center, Amsterdam, Netherlands); F.J. van Kemenade,
B. Stricker (Erasmus University Medical Center, Rotterdam, Netherlands); L. Overbeek, A. Gijsbers (PALGA, the
Nationwide Histopathology and Cytopathology Data Network and Archive, Houten, Netherlands)
Rainbow-TMA
collaborating
pathologists,
among others
A. de Bruïne (VieCuri Medical Center, Venlo); J.C. Beckervordersandforth (Maastricht University Medical Center,
Maastricht); J. van Krieken, I. Nagtegaal (Radboud University Medical Center, Nijmegen); W. Timens (University
Medical Center Groningen, Groningen); F.J. van Kemenade (Erasmus University Medical Center, Rotterdam);
M.C.H. Hogenes (Laboratory for Pathology Oost-Nederland, Hengelo); P.J. van Diest (University Medical Center
Utrecht, Utrecht); R.E. Kibbelaar (Pathology Friesland, Leeuwarden); A.F. Hamel (Stichting Samenwerkende
Ziekenhuizen Oost-Groningen, Winschoten); A.T.M.G. Tiebosch (Martini Hospital, Groningen); C. Meijers
(Reinier de Graaf Gasthuis/ S.S.D.Z., Delft); R. Natté (Haga Hospital Leyenburg, The Hague); G.A. Meijer
(VU University Medical Center, Amsterdam); J.J.T.H. Roelofs (Academic Medical Center, Amsterdam);
R.F. Hoedemaeker (Pathology Laboratory Pathan, Rotterdam); S. Sastrowijoto (Orbis Medical Center, Sittard);
M. Nap (Atrium Medical Center, Heerlen); H.T. Shirango (Deventer Hospital, Deventer); H. Doornewaard (Gelre
Hospital, Apeldoorn); J.E. Boers (Isala Hospital, Zwolle); J.C. van der Linden (Jeroen Bosch Hospital, Den
Bosch); G. Burger (Symbiant Pathology Center, Alkmaar); R.W. Rouse (Meander Medical Center, Amersfoort);
P.C. de Bruin (St. Antonius Hospital, Nieuwegein); P. Drillenburg (Onze Lieve Vrouwe Gasthuis, Amsterdam);
C. van Krimpen (Kennemer Gasthuis, Haarlem); J.F. Graadt van Roggen (Diaconessenhuis, Leiden); S.A.J.
Loyson (Bronovo Hospital, The Hague); J.D. Rupa (Laurentius Hospital, Roermond); H. Kliffen (Maasstad
Hospital, Rotterdam); H.M. Hazelbag (Medical Center Haaglanden, The Hague); K. Schelfout
(Stichting Pathologisch en Cytologisch Laboratorium West-Brabant, Bergen op Zoom); J. Stavast (Laboratorium
Klinische Pathologie Centraal Brabant, Tilburg); I. van Lijjnschoten (PAMM Laboratory for Pathology and Medical
Microbiology, Eindhoven); K. Duthoi (Amphia Hospital, Breda)
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